Q: Capacity to carry oxygen by sickle cell hemoglobin is reduced due to
A: Sickle cell disease is a group of disorders of blood generally inherited from parents to their…
Q: During MRNA splicing... intron-exon boundaries are marked by exon junction complexes. the 5' cap and…
A: mRNA splicing is a process in which a newly-made precursor mRNA transcript gets converted into a…
Q: Termination of DNA transcription in prokaryotes can be Question 22 options: intrinsic or…
A: Termination of transcription is the process by which RNA polymerase-catalyzed RNA synthesis on a DNA…
Q: Mutations that are not genetically inherited are called (A) If this type of mutation alters genes…
A: DNA Deoxyribonucleic acid or DNA is a long chain polymer that present inside the nucleus of the DNA…
Q: The human genes that convey a susceptibility to hereditary nonpolyposis colorectal cancer are genes…
A: Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is a genetic…
Q: Mutations in genes encoding chromatin-remodeling complexes have been identified in high frequencies…
A: A mutation is a change that occurs in the deoxyribonucleic acid (DNA)when it is damaged or changed…
Q: Describe the theory of heterochromatinization and what this theory predicts about global gene…
A: Introduction :- Heterochromatinization is the process by which portions of the genome become…
Q: graduate student wants to isolate cells from a patient and grow them perpetually in culture to study…
A: The correct answers are as follows- A. Telomerase C. MDM2 A graduate student wants to isolate cells…
Q: 3). Consider the four mutations (i-iv) described below: i. One of the mutations causing cystic…
A: A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur…
Q: Based on what you know about the development of cancer, was the mutation in your allele(kwas) the…
A: A mutation is defined as a change in the sequence of DNA. It may occur due mistakes during the…
Q: Cancer cells removed from a patient's tumor have increased gene expression of several hundred genes…
A: Cancer Cancer if a kind of disorder which caused by several means like drug, radiation, malfunction…
Q: The most prominent mutation of ERBB2 in breast cancer is L755S. What kind of mutation is this? Is…
A: Mutation is the change in structure of a gene, which results in variation. These variations can be…
Q: How many of the mutations listed below would lead to excessive cell growth when the cell was either…
A: Excessive growth occurs when a cell continuously divides and when there is no cell cycle arrest. Myc…
Q: How does reverse methylation affect gene expression? Select one: o a. The gene is turned off, but…
A: Hello. Since your question has multiple parts, we will solve first question for you. If you want…
Q: Refer to the experimental approach (i.e., very briefly describe) and give the results AND…
A: (A) MicroRNA-25-3p (Mir-25-3 p) levels were measured in malignant and normal surrounding tissue…
Q: refer to this paper: Cytosolic Malic Enzyme 1 (ME1) Mediates High Fat Diet-Induced Adiposity,…
A: Here we are given the name of the research paper "Cytosolic Malic Enzyme 1 (ME1) Mediates High Fat…
Q: You are looking at the results of a western blot from the lysates of cells harvested from a…
A: When you observe an increased expression of INK4-p16 in the lysates of cells harvested from a…
Q: 7) The protein VEGF plays an important role in stimulating the formation of new blood vessels. In…
A: VEGF ( vascular endothelial growth factor ) is responsible for the growth of new vessels. In…
Q: Which of the following defects in RAS would be tumorigenic? multiple answers A. Deletion of…
A: Ras is a nucleotide binding protein that is responsible for cell division, growth and…
Q: E. coli has five genes that code for enzymes that make tryptophan. These genes are regulated by a…
A: Tryptophan operon found in E.coli and some other bacteria. It is group of genes which encodes for…
Q: Cancer Cells need A.I.R in order to survive and proliferate. What does this stand for? a.…
A: Oncogene activation requires genetic alterations in cellular protooncogenes. The result of these…
Q: Please help me with the cell biology question below.
A: Interpretation of the DataA: miR-31 Expression in Tumor vs. Non-tumor SamplesThis part of the…
Q: The answer did not address why most cancer mutations occur upstream of MAPK (ie. RAS (10-20% NRAS…
A: RAS protein is monomeric G protein , it will belongs in the GTPase super family of intracellular…
Q: How does the sigma factor of E. coli RNA polymerase bind to promoters? Question 10 options: a…
A: Two grooves of DNA are formed by an antiparallel arrangement of DNA strands. They are sites for…
Q: could you explain a bit more what this sentences mean: The information displayed demonstrates a…
A: Dentate gyrus is an important region in the hippocampal formation of the brain. This portion is…
Q: You are a scientist studying drug resistance in cancer. You are particularly interested in ABCB1, a…
A: Cancer causes the uncontrolled growth of abnormal cells and dynamic altering in the genome. Common…
Q: 1. Gene expression can be regulated at the level of a) transcription b) RNA stability c) translation…
A: Note - Since you have asked multiple questions, we will solve the first question for you. If you…
Q: Which of the following accurately describes the function of HOTAIR? O It is a long non-coding RNA…
A: Option 1 is the correct answer.
Q: with Nonpolyposis colorectal cancer and his biopsy pathology report reveals a defect in some TSGs…
A: Non polyposis rectal cancer may have a hereditary origin linked to it as few mutations in certain…
Q: Which of the following is a likely outcome of Rifampin treatment? Transcriptional elongation is…
A: Answer. Rifampicin is a major derivative of the antibiotic rifamycin. This antibiotic binds to the…
Q: A greater number of protocadherin genes ____.
A: Protocadherins are a family of cell adhesion molecules, and they play a crucial role in neuronal…
Q: 1). Tumor suppressor proteins monitor DNA and detect damage. Some cancers evade this detection by…
A: Tumor suppressor proteins helps to control cell growth and activated in response to DNA damage and…
Q: A study was conducted to determine the importance of Nucleoid Associated Proteins (NAPs) by deleting…
A: 1- Nucleoid-associated protein (NAPs): These are small DNA binding proteins which can alter the DNA…
Step by step
Solved in 3 steps
- The Adaptive Immune Response Is a Specific Defense Against Infection In cystic fibrosis gene therapy, scientists propose the use of viral vectors to deliver normal genes to cells in the lungs. What immunological risks are involved in this procedure?Although it is well known that X-rays cause mutations, they are routinely used to diagnose medical problems, including potential tumors, broken bones, and dental cavities. Why is this done? What precautions need to be taken?What is the difference between a proto-oncogene and a tumor-suppressor gene?
- New drugs are being developed that decrease DNA methylation and prevent the removal of acetyl groups from histone proteins. Explain how these drugs could affect gene expression to help kill tumor cells.Who Owns Your Genome? John Moore, an engineer working on the Alaska oil pipeline, was diagnosed in the mid-1970s with a rare and fatal form of cancer known as hairy cell leukemia. This disease causes overproduction of one type of white blood cell known as a T lymphocyte. Moore went to the UCLA Medical Center for treatment and was examined by Dr. David Golde, who recommended that Moores spleen be removed in an attempt to slow down or stop the cancer. For the next 8 years, John Moore returned to UCLA for checkups. Unknown to Moore, Dr. Golde and his research assistant applied for and received a patent on a cell line and products of that cell line derived from Moores spleen. The cell line, named Mo, produced a protein that stimulates the growth of two types of blood cells that are important in identifying and killing cancer cells. Arrangements were made with Genetics Institute, a small start-up company, and then Sandoz Pharmaceuticals, to develop the cell line and produce the growth-stimulating protein. Moore found out about the cell line and its related patents and filed suit to claim ownership of his cells and asked for a share of the profits derived from the sale of the cells or products from the cells. Eventually, the case went through three courts, and in July 1990n years after the case beganthe California Supreme Court ruled that patients such as John Moore do not have property rights over any cells or tissues removed from their bodies that are used later to develop drugs or other commercial products. This case was the first in the nation to establish a legal precedent for the commercial development and use of human tissue. The National Organ Transplant Act of 1984 prevents the sale of human organs. Current laws allow the sale of human tissues and cells but do not define ownership interests of donors. Questions originally raised in the Moore case remain largely unresolved in laws and public policy. These questions are being raised in many other cases as well. Who owns fetal and adult stem-cell lines established from donors, and who has ownership of and a commercial interest in diagnostic tests developed through cell and tissue donations by affected individuals? Who benefits from new genetic technologies based on molecules, cells, or tissues contributed by patients? Are these financial, medical, and ethical benefits being distributed fairly? What can be done to ensure that risks and benefits are distributed in an equitable manner? Gaps between technology, laws, and public policy developed with the advent of recombinant DNA technology in the 1970s, and in the intervening decades, those gaps have not been closed. These controversies are likely to continue as new developments in technology continue to outpace social consensus about their use. Should the physicians at UCLA have told Mr. Moore that his cells and its products were being commercially developed?Who Owns Your Genome? John Moore, an engineer working on the Alaska oil pipeline, was diagnosed in the mid-1970s with a rare and fatal form of cancer known as hairy cell leukemia. This disease causes overproduction of one type of white blood cell known as a T lymphocyte. Moore went to the UCLA Medical Center for treatment and was examined by Dr. David Golde, who recommended that Moores spleen be removed in an attempt to slow down or stop the cancer. For the next 8 years, John Moore returned to UCLA for checkups. Unknown to Moore, Dr. Golde and his research assistant applied for and received a patent on a cell line and products of that cell line derived from Moores spleen. The cell line, named Mo, produced a protein that stimulates the growth of two types of blood cells that are important in identifying and killing cancer cells. Arrangements were made with Genetics Institute, a small start-up company, and then Sandoz Pharmaceuticals, to develop the cell line and produce the growth-stimulating protein. Moore found out about the cell line and its related patents and filed suit to claim ownership of his cells and asked for a share of the profits derived from the sale of the cells or products from the cells. Eventually, the case went through three courts, and in July 1990n years after the case beganthe California Supreme Court ruled that patients such as John Moore do not have property rights over any cells or tissues removed from their bodies that are used later to develop drugs or other commercial products. This case was the first in the nation to establish a legal precedent for the commercial development and use of human tissue. The National Organ Transplant Act of 1984 prevents the sale of human organs. Current laws allow the sale of human tissues and cells but do not define ownership interests of donors. Questions originally raised in the Moore case remain largely unresolved in laws and public policy. These questions are being raised in many other cases as well. Who owns fetal and adult stem-cell lines established from donors, and who has ownership of and a commercial interest in diagnostic tests developed through cell and tissue donations by affected individuals? Who benefits from new genetic technologies based on molecules, cells, or tissues contributed by patients? Are these financial, medical, and ethical benefits being distributed fairly? What can be done to ensure that risks and benefits are distributed in an equitable manner? Gaps between technology, laws, and public policy developed with the advent of recombinant DNA technology in the 1970s, and in the intervening decades, those gaps have not been closed. These controversies are likely to continue as new developments in technology continue to outpace social consensus about their use. Do you think that donors or patients who provide cells and/or tissues should retain ownership of their body parts or should share in any financial benefits that might derive from their use in research or commercial applications?
- Which of the following mutations will result in cancer? a. homozygous recessive mutation in a tumor-suppressor gene coding for a nonfunctional protein b. dominant mutation in a tumor-suppressor gene in which the normal protein product is overexpressed c. homozygous recessive mutation in which there is a deletion in the coding region of a proto-oncogene, leaving it nonfunctional d. dominant mutation in a proto-oncogene in which the normal protein product is overexpressedBriefly describe the function of the following in protein synthesis. a. rRNA b. tRNA c. mRNAThe following is a portion of a protein: met-trp-tyr-arg-gly-pro-thr-Various mutant forms of this protein have been recovered. Using the normal and mutant sequences, determine the DNA and mRNA sequences that code for this portion of the protein, and explain each of the mutations. a. met-trp- b. met-cys-ile-val-val-leu-gln- c. met-trp-tyr-arg-ser-pro-thr- d. met-trp-tyr-arg-gly-ala-val-ile-ser-pro-thr-
- Which of the following statements about cancer is false? (a) oncogenes arise from mutations in proto-oncogenes (b) tumor suppressor genes normally interact with growth-inhibiting factors to block cell division (c) more than 120 cancer-driving genes have been discovered (d) oncogenes were first discovered in mouse models for cancer (e) the development of cancer is usually a multistep process involving both oncogenes and mutated tumor suppressor genesFigure 9.10 In certain cancers, the GTPase activity of the RAS G-protein is inhibited. This means that the RAS protein can no longer hydrolyze GTP into GDP What effect would this have on downstream cellular events?IS. Alternative splicing has been estimated to occur in more than 95% of multi-exon genes. Which of the following is not an evolutionary advantage of alternative splicing? Alternative splicing increases diversity without increasing genome size Different gene isoforms can be expressed in different tissues Alternative splicing creates shorter mRNA transcripts Different gene isoforms can be expressed during different stages of development.
